To understand why METTL3 has attracted such intense scrutiny, it helps to start with the chemistry. N6-methyladenosine is the most abundant internal chemical modification found in messenger RNA across eukaryotic cells, and it is installed and removed dynamically by dedicated enzyme complexes. METTL3 functions as the chief catalytic subunit of the methyltransferase complex, working alongside METTL14, which provides structural support, and accessory factors such as WT1-associated protein, VIRMA/KIAA1429, RBM15 and ZC3H13, which help target the complex to specific RNA substrates. The review details METTL3’s modular architecture: a central methyltransferase domain that binds the universal methyl donor S-adenosylmethionine, a zinc finger domain and a leading helix that contribute to substrate recognition, and a nuclear localization signal that governs where in the cell the protein operates. This structural organization allows METTL3 to deposit methyl marks onto thousands of RNA transcripts, altering their stability, translation efficiency, splicing and export without changing the underlying genetic sequence.

Because m6A methylation acts post-transcriptionally, it gives cancer cells a rapid and reversible way to reprogram gene expression. The review documents how METTL3 expression is itself regulated by an array of upstream signals, including cigarette smoke condensate in lung cancers, lactylation of the histone mark H3K18 in pancreatic ductal adenocarcinoma, the transcription factor Yin-yang 1, the hepatitis B X-interacting protein in hepatoblastoma, and the peptidyl prolyl isomerase PIN1. Once elevated, METTL3 methylates transcripts encoding drivers of proliferation, invasion and metabolic adaptation in malignancies ranging from acute myeloid leukemia and chronic myeloid leukemia to pancreatic, colorectal, gastric and esophageal cancers, hepatocellular carcinoma, glioblastoma, bladder cancer, ovarian cancer, prostate cancer, osteosarcoma and lung adenocarcinoma. In leukemia in particular, pharmacological inhibition of METTL3 has emerged as an active therapeutic strategy, with experimental inhibitors demonstrating that the enzyme is a druggable target rather than an incidental marker.

The most consequential portion of the review, however, concerns tumor immune escape, the process by which malignant cells avoid recognition and destruction by cytotoxic T lymphocytes, natural killer cells and other immune effectors. The authors argue that METTL3 operates along two parallel routes. The first is intrinsic: within tumor cells, METTL3-mediated methylation of specific transcripts triggers metabolic reprogramming that changes what nutrients the tumor consumes and what metabolites it releases into its surroundings. In several cancer types, METTL3 upregulates glycolytic enzymes such as hexokinase 2, intensifying aerobic glycolysis and depleting glucose from the microenvironment while flooding it with lactate and other immunosuppressive metabolites. In hepatocellular carcinoma associated with non-alcoholic fatty liver disease, METTL3 has been linked through the SREBP cleavage activating protein to lipid metabolic shifts that further distort immune signaling. These metabolic alterations do more than feed the tumor; they create a biochemical landscape in which infiltrating lymphocytes struggle to maintain their effector functions.

The second route is extrinsic and centers on the functional remodeling of tumor-infiltrating immune cells themselves. The review synthesizes evidence that METTL3 activity in macrophages skews these cells toward a tumor-associated, pro-tumoral phenotype, in part by methylating transcripts tied to the complement receptor C5aR1 and other polarization regulators. In myeloid-derived suppressor cells, METTL3-dependent methylation enhances immunosuppressive output, including the catabolism that generates kynurenine, a metabolite that acts on the N-methyl-D-aspartate receptor and other targets to dampen T-cell responses. Dendritic cells, the professional antigen-presenting cells that ignite anti-tumor T-cell immunity, also fall under METTL3’s influence, with methylation of transcripts governing maturation and interferon signaling impairing their ability to present tumor-associated antigens. Even regulatory T cells, the immune system’s own brakes, appear subject to METTL3-controlled tuning, which can tilt the balance of the tumor immune microenvironment further toward suppression.

Immune checkpoint blockade, the class of therapies that includes antibodies against PD-1 and its ligand PD-L1, has transformed treatment for many cancers but fails in a majority of patients. The review makes the case that METTL3 is deeply entangled with this variability. In lung adenocarcinoma, METTL3-mediated methylation influences splicing factors such as serine-arginine protein kinase 1, affecting PD-L1 expression and thereby the tumor’s visibility to checkpoint inhibitors. In melanoma and other models, elevated METTL3 in tumor cells has been associated with reduced interferon-gamma responsiveness and diminished recruitment of cytotoxic T lymphocytes, whereas loss of METTL3 can restore inflammatory chemokine production and sensitize tumors to anti-PD-1 therapy. Conversely, METTL3 activity within T cells themselves regulates their differentiation, integrin beta 1-mediated trafficking, granzyme B production and persistence, meaning that the same enzyme can either undermine or support immunotherapy depending on which cell compartment is examined. This cell-type-specific duality, the authors emphasize, is precisely why a systems-level understanding of the METTL3 network is needed before the enzyme can be safely targeted in combination regimens.

The clinical dimension of the review extends to biomarker discovery. Across multiple tumor types, METTL3 expression profiles correlate with disease stage, immune infiltration patterns, immune checkpoint molecule abundance and patient survival, suggesting that METTL3 levels in tumor biopsies could one day help stratify patients for immunotherapy or identify those likely to experience hyperprogression. The authors also survey emerging therapeutic approaches beyond small-molecule catalytic inhibitors, including RNA-targeted strategies such as antisense oligonucleotides and targeted protein degradation, as well as rational combinations that pair METTL3 inhibition with immune checkpoint blockade, metabolic interventions or epigenetic drugs. The concept of topical immune modulation, in which RNA-modification biology is exploited to reprogram immune cells locally within the tumor, features among the forward-looking therapeutic ideas discussed.

Yet the review is equally candid about the gaps that remain. The complete molecular network connecting METTL3 to tumor immune escape has not been systematically mapped, and many of the individual methylated transcripts responsible for the phenotypes described above have been characterized only in isolation. It is not always clear whether METTL3’s effects on immunity are direct, mediated through methylation of immune-regulatory transcripts, or indirect, secondary to its influence on tumor metabolism and growth. Context dependence complicates the picture further: METTL3 appears to act as an oncogene in several cancers but has been reported to exert tumor-suppressive effects in others, and its activity in immune cells can either restrain or promote anti-tumor responses depending on the cell type and disease setting. Resolving these contradictions, the authors argue, will require single-cell multi-omics approaches that can trace m6A deposition, transcript output and immune phenotype simultaneously at cellular resolution in human tumors.

The overarching message is that METTL3 should be viewed as a critical molecular hub bridging the intrinsic properties of cancer cells and the immune responses of the surrounding microenvironment. As the most prevalent internal RNA modification in eukaryotes, m6A methylation offers tumors a fast, flexible and reversible layer of gene control, and METTL3 is the enzyme that wields it. Whether delivered as a standalone epitranscriptomic therapy or woven into combination strategies with checkpoint inhibitors and metabolic drugs, precise targeting of METTL3 represents a highly promising anti-tumor frontier. The authors caution that translating that promise into clinical benefit will depend on refined dissection of the regulatory network governing tumor immune escape and on the development of highly specific agents that can reach the right cells at the right time. For now, the review consolidates a rapidly growing literature into a coherent framework, positioning the RNA methyltransferase that was once studied as a matter of basic biochemistry at the center of the fight against cancer’s ability to hide.

Subject of Research: The role of the m6A RNA methyltransferase METTL3 in tumor immune escape and cancer treatment

Article Title: Methyltransferase-like 3: structure, biological function and role in tumor immune escape and treatment

Article References: Liu, G., Zhu, Y., Zhang, J., Wu, J., Liao, M., Zhao, J., Guo, M., & Xu, L. (2026). Methyltransferase-like 3: structure, biological function and role in tumor immune escape and treatment. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08960-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08960-y

Keywords: METTL3, m6A methylation, tumor immune escape, epitranscriptomics, RNA modification, tumor microenvironment, immune checkpoint blockade, metabolic reprogramming, immunotherapy, cancer epigenetics, tumor-associated macrophages, PD-L1

The discovery adds to growing evidence that the genome contains many functional peptides hidden within RNA molecules annotated as long noncoding RNAs. Long noncoding RNAs, or lncRNAs, are generally defined as transcripts longer than 200 nucleotides that do not serve as conventional templates for large proteins. Increasingly, however, scientists have found that some lncRNAs contain short open reading frames capable of producing micropeptides. These molecules can be only a few dozen or a few hundred amino acids long, yet they may regulate signaling complexes, membrane processes and gene expression. In this case, the researchers traced an immune-suppressive activity associated with the lncRNA gene USP30-AS1 to a peptide encoded within it. They designated the peptide USP30-AS1-encoded immune suppressor, abbreviated UEIS.

UEIS was found to be highly expressed in tumor-associated macrophages, immune cells that accumulate within cancers and can be reprogrammed by the tumor microenvironment. Macrophages are highly adaptable: depending on the signals they receive, they can support inflammation and attack abnormal cells, or promote tissue repair, blood-vessel formation and tumor growth. In the cancer setting, tumor-associated macrophages frequently acquire a protumorigenic state. Rather than efficiently supporting cytotoxic lymphocytes, they can help create an immune-permissive environment in which malignant cells survive, invade surrounding tissue and resist therapy. According to the study, UEIS contributes to this transition by suppressing macrophage interferon responses and thereby reducing the conditions needed for effective antitumor T cell activity.

The pathway targeted by UEIS normally functions as an intracellular alarm system for abnormal DNA. When tumor-derived DNA reaches the cell cytoplasm, it can be detected by the enzyme cGAS, which synthesizes the signaling molecule cyclic GMP–AMP. This molecule activates the adaptor protein STING, initiating a cascade involving the kinase TBK1 and downstream transcription factors that stimulate production of type I interferons. These interferons, including interferon-beta and related molecules, can strengthen antigen presentation, activate innate immune cells and help recruit and sustain T cells capable of attacking cancer. The pathway is therefore considered one of the most important bridges between the detection of tumor-associated DNA and the development of antitumor immunity.

The researchers found that UEIS is not simply present in macrophages at a constant level. Instead, it is induced after tumoral DNA activates the cGAS–STING pathway, but it appears relatively late in the response. This timing suggests that UEIS acts as a negative-feedback regulator. Early pathway activation can generate an interferon response, while later production of UEIS helps dampen that signal. Such feedback mechanisms are common in immune biology because uncontrolled interferon signaling can damage healthy tissue and trigger excessive inflammation. Cancer, however, may exploit this protective brake. By increasing UEIS after the initial alarm has sounded, tumor-associated macrophages can limit the duration or intensity of the immune response before it becomes sufficiently strong to support sustained tumor destruction.

At the molecular level, the study links UEIS to the formation of biomolecular condensates involving TBK1. Condensates are dynamic, membrane-free assemblies in which proteins and nucleic acids concentrate through multivalent interactions. They are increasingly recognized as organizing centers for signaling reactions, allowing pathway components to gather in the correct place and at the appropriate time. The researchers report that UEIS forms condensates with TBK1 and, through this interaction, interferes with the kinase’s association with STING. Because STING must engage TBK1 to efficiently transmit the signal generated by cytoplasmic DNA, disrupting that interaction effectively weakens the pathway downstream of DNA sensing. The result is reduced type I interferon signaling in macrophages.

The architecture of UEIS was also important to its activity. Experiments indicated that both an intrinsically disordered region and an alpha helix located at the extreme N terminus of the micropeptide were required for its function. Intrinsically disordered regions lack a single rigid three-dimensional structure and often enable flexible, multivalent interactions with several partners. They can be particularly important in the formation of biomolecular condensates because they provide repeated or adaptable binding surfaces. Alpha helices, by contrast, are structured elements that can create defined contact points within protein complexes. The findings suggest that UEIS may use its disordered region to support condensation while relying on its N-terminal helix to engage a signaling partner such as TBK1, although the precise atomic structure of the complex remains to be determined.

The therapeutic implications were tested with a peptide designed to disrupt UEIS–TBK1 condensation. Rather than attempting to eliminate the lncRNA or broadly inhibit the interferon pathway, the strategy focused on the physical interaction that gives UEIS its suppressive activity. The researchers report that the disrupting peptide inhibited UEIS function in tumor-associated macrophages. In experimental cancer models, treatment was associated with reduced tumor growth and a stronger response to immune checkpoint blockade. These results are significant because checkpoint inhibitors depend on an immune system capable of recognizing and attacking tumor cells. If macrophages suppress interferon signaling and maintain an immunosuppressive environment, blocking checkpoints alone may not be enough. Interrupting UEIS activity could help convert that environment into one more permissive for T cell function.

The findings position UEIS as a potential therapeutic target at the intersection of innate sensing, macrophage biology and cancer immunotherapy. They also illustrate why the search for cancer regulators cannot be limited to conventional protein-coding genes. A transcript previously categorized as noncoding can produce a short peptide that reorganizes a signaling pathway and changes the behavior of immune cells within tumors. Before the approach can be considered for clinical use, important questions will need to be addressed, including how selectively UEIS is expressed across cancers and normal tissues, whether disrupting its condensates causes unwanted inflammation, and how effectively the peptide can reach macrophages in human tumors. Nevertheless, the study offers a new explanation for how tumors attenuate cGAS–STING–type I interferon signaling and provides a possible way to strengthen immune checkpoint therapy by targeting a molecular brake embedded within a lncRNA.

Subject of Research: A micropeptide encoded by the lncRNA USP30-AS1 that suppresses cGAS–STING–type I interferon signaling in tumor-associated macrophages and promotes tumor growth.

Article Title: A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages.

Article References: Wang, X., Zhang, Y., Ma, J. et al. “A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages.” Nature Cancer 7, 1047–1063 (2026). https://doi.org/10.1038/s43018-026-01195-2

Image Credits: AI Generated

DOI: July 2026

Keywords: UEIS, USP30-AS1, micropeptide, long noncoding RNA, tumor-associated macrophages, cGAS–STING signaling, type I interferon, TBK1, biomolecular condensates, immune checkpoint blockade, cancer immunotherapy.

Colon cancer is notorious for its ability to metastasize or spread to other parts of the body, complicating treatment and severely affecting patient prognosis. The extracellular matrix (ECM), a complex network of proteins and carbohydrates, provides structural and biochemical support to surrounding cells, including tumor cells. Maintaining the stability of the ECM is crucial for preventing metastasis. The study by Wang et al. emphasizes the protective effects of curcumin on the ECM, suggesting that it could serve as a potent ally in halting tumor progression.

One of the most intriguing findings of this research is the identification of the HPSE/IL-6/STAT5 signaling axis as a pathway influenced by curcumin. Heparanase (HPSE) is an enzyme implicated in the degradation of the ECM, which, when activated, facilitates cancer cell migration and invasion. Curcumin appears to inhibit this pathway, suggesting it could limit the ability of cancer cells to escape their primary site and invade surrounding tissues. This represents a significant step forward in understanding how natural compounds may interfere with key processes involved in cancer metastasis.

Interleukin-6 (IL-6) is a pro-inflammatory cytokine that has been linked to various cancers, including colon cancer. Elevated levels of IL-6 contribute to a pro-tumor microenvironment that fosters cancer cell survival, proliferation, and migration. The study reveals that curcumin can effectively modulate IL-6 levels, thereby creating a less hospitable environment for cancer cells. This interaction highlights the essential link between inflammation and cancer progression, reinforcing the idea that anti-inflammatory strategies could be valuable in cancer treatment.

The STAT5 transcription factor is also pivotal in mediating the effects of IL-6 on tumor cells. By inhibiting the activation of STAT5, curcumin disrupts the signaling pathways that promote tumor growth and metastasis. This detail underscores the potential of curcumin as a dual-action agent that targets both the inflammatory and signaling components of cancer biology. Such multitarget strategies are becoming increasingly recognized as essential in developing effective cancer therapies.

Moreover, the study’s implications extend beyond curcumin’s direct effects on tumor cells. Curcumin also influences the stromal components of the tumor microenvironment, including fibroblasts and immune cells. By modulating these interactions, curcumin can alter how the tumor communicates with surrounding tissues, potentially enhancing the effectiveness of conventional therapies and improving overall patient outcomes. This aspect of curcumin’s action could lead to new combination therapies that integrate nutritional or herbal supplements with standard care protocols.

Importantly, this research adds scientific rigor to the longstanding tradition of using turmeric as a health supplement in various cultures. Traditionally recognized for its anti-inflammatory properties, curcumin is consumed in various forms—whether as a spice, in dietary supplements, or as an herbal remedy. The findings of Wang et al. provide a modern scientific basis for these traditional practices, suggesting thatdietary curcumin could be harnessed effectively in preventive strategies for colon cancer.

The featured study also prompts a comprehensive re-evaluation of the role of diet in cancer prevention. As the incidence of colorectal cancer continues to rise globally, understanding how dietary components affect cancer biology is vital. Curcumin’s protective properties could inspire dietary recommendations aimed at enhancing the intake of anti-cancer compounds, thereby fostering a proactive approach to health.

Critically, while these findings are promising, researchers stress the need for further clinical investigation. Human trials are essential to determine the appropriate dosages and delivery methods of curcumin for maximal therapeutic efficacy. Furthermore, understanding individual variations in metabolism and response to curcumin will be crucial. Future studies should focus on elucidating the mechanisms through which curcumin exerts its effects across diverse populations.

Finally, the attention drawn to curcumin puts a spotlight on the broader field of nutraceuticals and their potential role in oncology. As the paradigm shifts from conventional single-agent therapies to integrative approaches that consider diet and lifestyle, compounds like curcumin will likely play an essential role in shaping future cancer treatment protocols.

In summary, the study by Wang et al. solidifies curcumin’s position as a promising candidate for colon cancer treatment and prevention, emphasizing the importance of maintaining the extracellular matrix’s integrity while inhibiting pathways that facilitate cancer cell migration. As research continues to unfold, curcumin’s potential utility in improving clinical outcomes for patients with colon cancer bears significant promise for the future of cancer therapy.

Subject of Research: The protective effects of curcumin on the extracellular matrix and its role in inhibiting colon cancer metastasis through the HPSE/IL-6/STAT5 axis.

Article Title: Curcumin protects extracellular matrix to maintain microenvironmental stability inhibiting colon cancer metastasis through HPSE/IL-6/STAT5 axis.

Article References: Wang, X., Chai, R., Li, J. et al. Curcumin protects extracellular matrix to maintain microenvironmental stability inhibiting colon cancer metastasis through HPSE/IL-6/STAT5 axis. Sci Nat 112, 47 (2025). https://doi.org/10.1007/s00114-025-01988-y

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00114-025-01988-y

Keywords: Curcumin, colon cancer, metastasis, extracellular matrix, HPSE, IL-6, STAT5, anti-inflammatory, nutraceuticals, cancer therapy.